Cover Image
市場調查報告書

逆流性食道炎(胃食道逆流症):開發平台分析

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232845
出版日期 內容資訊 英文 86 Pages
訂單完成後即時交付
價格
Back to Top
逆流性食道炎(胃食道逆流症):開發平台分析 Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2016
出版日期: 2016年07月27日 內容資訊: 英文 86 Pages
簡介

胃液逆流到食道就稱之為胃食道逆流症(GERD),症狀有噁心、胃灼熱、嘔吐等。造成下食道括約肌(LES)開關失常的過度飲食、肥胖、懷孕、過油食物、部分醫藥品都是致病因子。

本報告函括全球逆流性食道炎(胃食道逆流症)治療藥的開發平台,提供您目前開發平台狀況和最新趨勢,藥物簡介,主要企業及開發中的產品評估等,為您概述為以下內容。

目錄

簡介

  • 分析範圍

逆流性食道炎(胃食道逆流症)概要

治療藥的開發

  • 逆流性食道炎(胃食道逆流症)開發中產品:概要
  • 逆流性食道炎(胃食道逆流症)開發中產品:比較分析

逆流性食道炎(胃食道逆流症):開發中的治療藥:各企業

逆流性食道炎(胃食道逆流症):開發中的治療藥:大學·研究機關別

逆流性食道炎(胃食道逆流症):開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

逆流性食道炎(胃食道逆流症):開發中的產品:各企業

逆流性食道炎(胃食道逆流症):開發中的產品:大學·研究機關別

逆流性食道炎(胃食道逆流症):治療藥的開發企業

  • Ahn-Gook Pharmaceutical Co., Ltd.
  • aRigen Pharmaceuticals, Inc.
  • Cempra, Inc.
  • Daewoong Pharmaceutical Co., Ltd.
  • Eisai
  • Ironwood Pharmaceuticals, Inc.
  • Johnson & Johnson
  • RaQualia Pharma Inc.
  • Shire Plc
  • Sucampo Pharmaceuticals, Inc.
  • Vecta Ltd.
  • Wockhardt Limited
  • Yuhan Corporation
  • Yuyu Pharma, Inc.

逆流性食道炎(胃食道逆流症):治療藥的評估

  • 單劑治療藥
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ARH-1029
  • cobiprostone
  • DWJ-1367
  • E-3710
  • Esomeprazole鎂
  • G-17DT
  • IW-3718
  • JNJ-26070109
  • omepurazoru
  • pantopurazoru
  • RQ-00000004
  • RQ-00000774
  • 消化性潰瘍治療藥
  • GERD及糖尿病性胃輕癱細葉冬青磷受體抑制劑
  • 消化器官疾病質子幫浦抑制劑
  • SSP-002358
  • tenatopurazoru
  • YH-4808
  • YY-DXR
    • 產品概要
    • 作用機制
    • R&D的進展

最新的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 關注的新聞·新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8310IDB

Summary

Global Markets Direct's, 'Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2016', provides an overview of the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastroesophageal Reflux Disease)
  • The report reviews pipeline therapeutics for Reflux Esophagitis (Gastroesophageal Reflux Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Reflux Esophagitis (Gastroesophageal Reflux Disease) therapeutics and enlists all their major and minor projects
  • The report assesses Reflux Esophagitis (Gastroesophageal Reflux Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Reflux Esophagitis (Gastroesophageal Reflux Disease)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) Overview
  • Therapeutics Development
    • Pipeline Products for Reflux Esophagitis (Gastroesophageal Reflux Disease) - Overview
    • Pipeline Products for Reflux Esophagitis (Gastroesophageal Reflux Disease) - Comparative Analysis
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics under Development by Companies
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics under Investigation by Universities/Institutes
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Products under Development by Companies
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Products under Investigation by Universities/Institutes
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Companies Involved in Therapeutics Development
    • Ahn-Gook Pharmaceutical Co., Ltd.
    • Alveonix AG
    • Cempra, Inc.
    • Daewoong Pharmaceutical Co., Ltd.
    • Eisai Co., Ltd.
    • Ironwood Pharmaceuticals, Inc.
    • Jeil Pharmaceutical Co., Ltd.
    • Johnson & Johnson
    • RaQualia Pharma Inc.
    • Vecta Ltd.
    • Wockhardt Limited
    • Yuyu Pharma, Inc.
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (lansoprazole + omeprazole) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Ax-8 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CEM-031 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DWJ-1367 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DWJ-206 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • E-3710 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • esomeprazole magnesium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • G-17DT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IW-3718 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-26070109 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JP-1366 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • netazepide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omeprazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pantoprazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RQ-00000774 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Potassium Transporting ATPase Alpha Chain 1 Inhibitor for Peptic Ulcers and Reflux Esophagitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Block Proton Pump for Gastrointestinal Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Tubulin for Barrett's Esophageal Adenocarcinoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tegoprazan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tenatoprazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TR-2A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YY-DXR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Product Development Milestones
    • Featured News & Press Releases
      • Mar 23, 2016: Ironwood Pharmaceuticals Initiates Phase IIb Clinical Trial of IW-3718 in Refractory Gastroesophageal Reflux Disease
      • Feb 18, 2016: RaQualia Receives a Patent Allowance for Acid Pump Antagonist in Korea
      • Oct 19, 2015: Ironwood Highlights Refractory GERD Research at the American College of Gastroenterology 2015 Annual Scientific Meeting
      • Feb 04, 2015: Ironwood Reports Positive Top-Line Data from Exploratory Phase IIa Trial Of IW-3718 in Refractory Gastroesophageal Reflux Disease
      • Mar 18, 2014: Ironwood Pharmaceuticals Initiates Phase II Clinical Study of IW-3718 in Refractory Gastroesophageal Reflux Disease
      • Sep 04, 2012: Santarus Announces Appellate Court Reversal In Part Of Zegerid Invalidity Decision
      • Mar 29, 2011: RaQualia Pharma Announces Successful Results From Phase I Study Of Acid Pump Antagonist
      • Apr 01, 2010: Santarus Announces Launch of ZEGERID OTC by Schering-Plough Consumer HealthCare
      • Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck
      • Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations
      • Dec 22, 2009: Santarus Receives Previously Announced $20 Million Milestone for FDA Approval of ZEGERID OTC
      • Dec 05, 2009: Santarus Receives FDA Approval for Immediate-Release Omeprazole
      • Dec 01, 2009: Santarus Announces FDA Approval of Schering-Plough HealthCare Products' ZEGERID OTC
      • Oct 26, 2009: Santarus To Present Positive Data From Two Investigator-Initiated Studies With ZEGERID At ACG 2009 Meeting
      • Oct 12, 2009: Santarus and Norgine Enter License for ZEGERID Immediate-Release Omeprazole Products in Europe
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), H2 2016
  • Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H2 2016
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Alveonix AG, H2 2016
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Cempra, Inc., H2 2016
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Eisai Co., Ltd., H2 2016
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2016
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Johnson & Johnson, H2 2016
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by RaQualia Pharma Inc., H2 2016
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Vecta Ltd., H2 2016
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Wockhardt Limited, H2 2016
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Yuyu Pharma, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, H2 2016
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects (Contd..1), H2 2016
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects (Contd..2), H2 2016
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products, H2 2016
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products (Contd..1), H2 2016
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products (Contd..2), H2 2016

List of Figures

  • Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), H2 2016
  • Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top